Recently, considerable progress has been made in the treatment of anaplastic lymphoma kinase (ALK)-rearranged non–small-cell lung cancer (NSCLC) with additional ALK-tyrosine kinase inhibitors (TKIs) [1–4]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.